Back to Research
Featured Study
SGLT2 Inhibitors Slow Kidney Decline—Even Without Diabetes
Published in New England Journal of Medicine
Expanded Summary
This global randomized controlled trial enrolled over 4,000 patients with CKD (stages 2–4) who did not have diabetes. Patients received either an SGLT2 inhibitor (such as dapagliflozin) or placebo and were followed for 36 months.
Key Outcomes
- Primary outcome
- Progression to kidney failure or a sustained ≥50% drop in eGFR.
- Results
- The treatment group had a 28% lower risk of reaching the primary outcome.
- Additional benefits
- Fewer cardiovascular events and hospitalizations were reported in the treatment group.
- Safety profile
- Mild increases in genital infections, but no rise in serious adverse events.
Implications
SGLT2 inhibitors are now being recommended by nephrology guidelines for many CKD patients—even if they don't have diabetes. This expands treatment options and could help delay dialysis in a broader population.
What This Means for You
If you have CKD but dondon'tapos;t have diabetes, talk to your healthcare provider about whether SGLT2 inhibitors might be appropriate for your treatment plan. These medications could help protect your kidney function and reduce other health risks.